相关临床试验
5
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1998
Available
1
20.0%
Unknown
3
60.0%
撤回
1
20.0%
暂无批准数据
- Northwest Biotherapeutics and SPIMACO entered a non-binding MOU to bring DCVax-L, a personalized dendritic cell vaccine for glioblastoma, to Saudi Arabia. - The collaboration covers regulatory approval through the Saudi FDA, commercialization, supply, and eventual localized manufacturing under a revenue-sharing model. - SPIMACO, a leading pharma company across 21 MENA markets, will lead marketing, sales, and distribution while NWBio retains all intellectual property rights. - The partnership aligns with Saudi Arabia's Vision 2030 plan to establish the Kingdom as a global hub for life sciences and biotechnology.
- Northwest Biotherapeutics has appointed Dr. Annalisa Jenkins, a distinguished biopharma leader with over 25 years of experience, as Strategic Adviser to advance its DCVax® dendritic cell-based cancer vaccine platform. - The company's lead program DCVax®-L for glioblastoma has completed a 331-patient Phase III trial and submitted a Marketing Authorization Application to the UK's MHRA for commercial approval. - The DCVax® platform is designed to address solid tumors, which represent approximately 90% of all cancers, with clinical trials encompassing 16 diverse tumor types. - Dr. Jenkins brings extensive expertise from executive roles at major pharmaceutical companies including Merck Serono and Bristol-Myers Squibb, plus experience as CEO of gene therapy company Dimension Therapeutics.
- The Cancer Vaccine Coalition and American Association for Cancer Research convened over 50 leading cancer vaccine researchers for a first-of-its-kind global think tank to coordinate progress in cancer immunity. - Current immunotherapies successfully treat only 20% of the deadliest cancers, while therapeutic cancer vaccines have the potential to expand success to the remaining 80% by creating cancer-killing T cells. - Clinical trials are currently underway across multiple cancer types including glioblastoma, melanoma, pancreatic, breast, ovarian, and liver cancers, showing promising signals of immune response and clinical benefit. - The initiative aims to align scientific priorities, improve research efficiency, integrate emerging technologies like AI-driven antigen prediction, and establish models for sustained global collaboration.
- Northwest Biotherapeutics has commenced construction of its first Grade C manufacturing suite at the Sawston, UK facility, which will more than double the company's current DCVax production capacity. - The transition from Grade B to Grade C manufacturing enables simultaneous production of multiple patient products and significantly reduces operational costs and complexity. - The company's Flaskworks closed system technology enables DCVax-L production in the more efficient Grade C environment, representing a key advancement for large-scale manufacturing. - Manufacturing operations in the new suite are expected to begin in Q2 2026, following approximately six months of construction and subsequent equipment installation and validation.
- Northwest Biotherapeutics has completed its acquisition of Advent BioServices Ltd., making it a wholly owned subsidiary to enable fully integrated operations and manufacturing scale-up. - The acquisition includes all of Advent's fixed assets, extensive cryostorage equipment, and intellectual property, while 19 million NWBio securities previously issued to Advent revert back to the company. - The strategic consolidation aims to streamline operations between London and Sawston GMP facilities, with plans to close London operations and focus resources on the Sawston facility and US capacity development. - The £1.4 million acquisition consideration will be paid in installments over two years, with potential acceleration following regulatory approval of DCVax-L for glioblastoma treatment.
- Northwest Biotherapeutics' Chief Technical Officer Dr. Marnix Bosch will present on "supercharged" dendritic cells with enhanced anti-tumor effects at the Frontiers in Cancer Immunotherapy Conference on June 16. - The company has completed a 331-patient Phase III trial of DCVax-L for glioblastoma and submitted a Marketing Authorization Application for commercial approval in the UK. - Northwest Biotherapeutics is developing DCVax-Direct for inoperable solid tumors, having completed a 40-patient Phase I trial with Phase II trials planned for this year.
